Brazil benefits from a program, known as the Partnership for Productive Development, that brings together government and the private sector to develop strategic products of interest to the Brazilian health system—including biosimilars of high-cost biologics that account for approximately half of annual drug spending.
In 2010, Brazil’s National Health Surveillance Agency (ANVISA) established criteria for biosimilar approval, forming a comprehensive pathway for these products for the first time. The guidelines, Collegiate Board Resolution 55/2010, provides 2 ways in which a biosimilar can be approved: comparability and individual development.
The comparability demonstration is similar to that described by the World Health Organization. Under Brazil’s comparability pathway, biosimilars require comparative data from preclinical as well as phase 1 and phase 3 clinical studies in relation to the reference product, and the extrapolation of indications is permitted. Robust pharmacovigilance systems, similar to those in place for the reference drug, are required.
Read more about biosimilars in Brazil.
However, the individual development pathway differs significantly from the comparability pathway; individual development requires comparative data only from preclinical trials and phase 3 confirmatory studies, with no requirement to produce comparative data from phase 1 studies. Extrapolation of indications for products developed in this manner are not permitted, and these products may not be treated as interchangeable with their references.
For both types of biosimilar products, explains a newly published paper, Brazil benefits from a program known as the Partnership for Productive Development (PPD), which brings together government and the private sector to develop strategic products of interest to the Brazilian health system—including biosimilars of the high-cost biologics that account for approximately half of annual drug spending.
In an arrangement that the paper calls a “win-win opportunity” for both government and private companies, under a PPD agreement, the master cell bank for a biologic is required by law to be transferred to the government organization participating in the agreement for use in manufacturing, and the biosimilar maker develops a product that will then be purchased directly by the Brazilian Ministry of Health. Thus, the government establishes a supply of a cost-reducing product, and the biosimilar developer ensures robust sales of its product. Biosimilars that are currently part of such agreements include rituximab, adalimumab, and bevacizumab.
The impact of such agreements on Brazil’s healthcare system has the potential to be significant. At the same time, nationalizing production of biosimilars presents an opportunity, say the paper's authors, for the nation to positive impact its trade balance, generate tax revenue, and provide jobs in Brazil.
Reference
Scheinberg MA, Felix PAO, Kos IA, Andrade MA, Azevedo VF. Partnership for productive development of biosimilar products: perspective of access to biological products in the Brazilian market. Einstein (Sao Paulo). 2018;16(3): eRW4175. doi: 10.1590/S1679-45082018RW4175.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio
March 24th 2025Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.